Ureteroscopy: Stents and Other Adjuncts

  • Patrick LowryEmail author


Ureteroscopy for the purpose of lithotripsy or stone extraction inevitably causes some degree of trauma to the ureter. Traditionally, ureteral stents were placed routinely to prevent renal colic or ureteral stricture formation. Although stenting effectively prevents the symptoms of colic, it may cause symptoms such as bladder irritation, flank pain, dysuria, or hematuria.

In the early years of ureteroscopy, the use of larger caliber rigid scopes always required dilation and subsequent stenting; and at that time, only externalized ureteral catheters of relatively rigid materials were available. These were uncomfortable, and the symptoms required hospitalization. Over time, indwelling double J-type stents of more tolerable materials were developed, which allowed for internal stenting, decreased levels of patient symptoms, and outpatient surgery. As advances in technology have given us scopes with decreasing diameter, surgery has become less traumatic for the ureteral tissues, prompting Urologists to question the need for routine stenting. Clearly, properly selected ureteroscopic procedures may be routinely performed without the need for postoperative stents.

From a drainage standpoint, stents function without problem. However, they cause morbidity, which may be moderate for some patients and much more severe for others. These symptoms have not only resulted in recent advancements but drive current areas of research into stent design. Future study must elucidate the mechanism that causes morbidity, which will in turn allow for better-directed research in stent design and medical management of symptoms.


Flank Pain Renal Colic Stent Design Ureteral Stents Stent Removal 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Harmon WJ, Sershon PD, Blute ML, Patterson DE, Segura JW. Ureteroscopy: current practice and long-term complications. J Urol. 1997;157(1):28–32.PubMedCrossRefGoogle Scholar
  2. 2.
    Finney RP. Experience with new double-J ureteral stent. J Urol. 1978;120(6):678–81.PubMedGoogle Scholar
  3. 3.
    Saltzman B. Ureteral stents: indications, variations, and complications. Urol Clin North Am. 1988;15(3):481–91.PubMedGoogle Scholar
  4. 4.
    Zimskind PD, Fetter TR, Wilkerson JL. Clinical use of long-term indwelling silicone rubber ureteral splints injected cystoscopically. J Urol. 1967;97(5):840–4.PubMedGoogle Scholar
  5. 5.
    Hepperlen TW, Mardis HK, Kammandel H. Self-retained internal ureteral stents: a new approach. J Urol. 1978;119(6):731–4.PubMedGoogle Scholar
  6. 6.
    Mardis HK, Kroeger RM. Ureteral stents: materials. Urol Clin North Am. 1988;15(3):471–9.PubMedGoogle Scholar
  7. 7.
    Hepperlen TW, Mardis HK, Malashock E. Spontaneous breakage of polyethylene double pigtail ureteral stents (abstract). Proceedings of the American Urological Association. 1982: 198.Google Scholar
  8. 8.
    Christman MS, L’esperance JO, Choe CH, Stroup SP, Auge BK. Analysis of ureteral stent compression force and its role in malignant obstruction. J Urol. 2009;181(1):392–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Goldsmith ZG, Wang AJ, Bañez LL, Lipkin ME, Ferrandino MN, Preminger GM, et al. Outcomes of metallic stents for malignant ureteral obstruction. J Urol. 2012;188(3):851–5.PubMedCrossRefGoogle Scholar
  10. 10.
    Kulkarni RP, Bellamy EA. A new thermo-expandable shape-memory nickel-titanium alloy stent for the management of ureteric strictures. BJU Int. 1999;83(7):755–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Kulkarni R, Bellamy E. Nickel-titanium shape memory alloy Memokath 051 ureteral stent for managing long-term ureteral obstruction: 4-year experience. J Urol. 2001;166(5):1750–4.PubMedCrossRefGoogle Scholar
  12. 12.
    Zaman F, Poullis C, Bach C, Moraitis K, Junaid I, Buchholz N, et al. Use of a segmental thermoexpandable metal alloy stent in the management of malignant ureteric obstruction: a single centre experience in the UK. Urol Int. 2011;87(4):405–10.PubMedCrossRefGoogle Scholar
  13. 13.
    Moon YT, Kerbl K, Pearle MS, Gardner SM, McDougall EM, Humphrey P, et al. Evaluation of optimal stent size after endourologic incision of ureteral strictures. J Endourol. 1995;9(1):15–22.PubMedCrossRefGoogle Scholar
  14. 14.
    Danuser H, Hochreiter WW. Influence of stent size on the success of antegrade endopyelotomy for primary ureteropelvic junction obstruction: results of 2 consecutive series. J Urol. 2001;166(3):902–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Dunn MD, Portis AJ, Kahn SA, Yan Y, Shalhav AL, Elbahnasy AM, et al. Clinical effectiveness of new stent design: randomized single-blind comparison of tail and double-pigtail stents. J Endourol. 2000;14(2):195–202.PubMedCrossRefGoogle Scholar
  16. 16.
    Lingeman JE, Preminger GM, Goldfischer ER, Krambeck AE. Comfort study team. Assessing the impact of ureteral stent design on patient comfort. J Urol. 2009;181(6):2581–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Hosking DH, McColm SE, Smith WE. Is stenting following ureteroscopy for removal of distal ureteral calculi necessary? J Urol. 1999;161(1):48–50.PubMedCrossRefGoogle Scholar
  18. 18.
    Hollenbeck BK, Schuster TG, Faerber GJ, Wolf Jr JS. Routine placement of ureteral stents is unnecessary after ureteroscopy for urinary calculi. Urology. 2001;57(4):639–43.PubMedCrossRefGoogle Scholar
  19. 19.
    Hollenbeck BK, Schuster TG, Seifman BD, Faerber GJ, Wolf Jr JS. Identifying patients who are suitable for stentless ureteroscopy following treatment of urolithiasis. J Urol. 2003;170(1):103–6.PubMedCrossRefGoogle Scholar
  20. 20.
    Davis DM. Intubated uroterostomy: a new operation for ureteral and ureteropelvic strictures. Surg Gynecol Obstet. 1943;76:513–23.Google Scholar
  21. 21.
    Giannarini G, Keeley Jr FX, Valent F, et al. Predictors of morbidity in patients with indwelling ureteric stents: results of a prospective study using the validated Ureteric Stent Symptoms Questionnaire. BJU Int. 2011;107(4):648–54.PubMedCrossRefGoogle Scholar
  22. 22.
    Rane A, Saleemi A, Cahill D, Sriprasad S, Shrotri N, Tiptaft R. Have stent-related symptoms anything to do with placement technique? J Endourol. 2001;15(7):741–5.PubMedCrossRefGoogle Scholar
  23. 23.
    Lamb AD, Vowler SL, Johnston R, Dunn N, Wisemann OJ. Meta-analysis showing the beneficial effect of a-blockers on ureteric stent discomfort. BJU Int. 2011;108(11):1894–902.PubMedCrossRefGoogle Scholar
  24. 24.
    Yakoubi R, Lemdani M, Monga M, Villers A, Koenig P. Is there a role for a-blockers in ureteral stent related symptoms? A systematic review and meta-analysis. J Urol. 2011;186(3):928–34.PubMedCrossRefGoogle Scholar
  25. 25.
    Norris RD, Sur RL, Springhart WP, Marguet CG, Mathias BJ, Pietrow PK, et al. A prospective, randomized, double-blinded placebo-controlled comparison of extended release oxybutynin versus phenazopyridine for the management of postoperative ureteral stent discomfort. Urology. 2008;71(5):792–5.PubMedCrossRefGoogle Scholar
  26. 26.
    Yoshimura K, Yoshioka T, Miyake O, Honda M, Yamaguchi S, Koide T, et al. Glycosaminoglycans in crystal-surface binding substances and their role in calcium oxalate crystal growth. Br J Urol. 997;80(1):64–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Angell AH, Resnick MI. Surface interaction between glycosaminoglycans and calcium oxalate. J Urol. 1989;141:1255–8.PubMedGoogle Scholar
  28. 28.
    Hildebrandt P, Sayyad M, Rzany A, Schaldach M, Seiter H. Prevention of surface encrustation of urological implants by coating with inhibitors. Biomaterials. 2001;22(5):503–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Cauda F, Cauda V, Fiori C, Onida B, Garrone E. Heparin coating on ureteral Double J stents prevents encrustations: an in vivo case study. J Endourol. 2008;22(3):465–72.PubMedCrossRefGoogle Scholar
  30. 30.
    Laube N, Kleinen L, Bradenahl J, Meissner A. Diamond-like carbon coatings on ureteral stents–a new strategy for decreasing the formation of crystalline bacterial biofilms? J Urol. 2007;177(5):1923–7.PubMedCrossRefGoogle Scholar
  31. 31.
    Lange D, Elwood CN, Choi K, Hendlin K, Monga M, Chew BH. Uropathogen interaction with the surface of urological stents using different surface properties. J Urol. 2009;182(3):1194–200.PubMedCrossRefGoogle Scholar
  32. 32.
    Elwood CN, Chew BH, Seney S, Jass J, Denstedt JD, Cadieux PA. Triclosan inhibits uropathogenic Escherichia coli-stimulated tumor necrosis factor-alpha secretion in T24 bladder cells in vitro. J Endourol. 2007;21(10):1717–22.CrossRefGoogle Scholar
  33. 33.
    Mendez-Probst CE, Goneau LW, Macdonald KW, Nott L, Seney S, Elwood CN, et al. The use of triclosan eluting stents effectively reduces ureteral stent symptoms: a prospective randomized trial. BJU Int. 2012;110(5):749–54.PubMedCrossRefGoogle Scholar
  34. 34.
    Liatsikos EN, Karnabatidis D, Kagadis GC, Rokkas K, Constantinides C, Christeas N, et al. Application of paclitaxel-eluting metal mesh stents within the pig ureter: an experimental study. Eur Urol. 2007;51(1):217–23.PubMedCrossRefGoogle Scholar
  35. 35.
    Beiko DT, Watterson JD, Knudsen BE, Nott L, Pautler SE, Brock GB, et al. Doubleblind randomized controlled trial assessing the safety and efficacy of intravesical agents for ureteral stent symptoms after extracorporeal shockwave lithotripsy. J Endourol. 2004;18(8):723–30.PubMedGoogle Scholar
  36. 36.
    Krambeck AE, Walsh RS, Denstedt JD, Preminger GM, Li J, Evans JC, et al. A novel drug eluting ureteral stent: a prospective, randomized, multicenter clinical trial to evaluate the safety and effectiveness of a ketorolac loaded ureteral stent. J Urol. 2010;183(3):1037–42.PubMedCrossRefGoogle Scholar
  37. 37.
    Lingeman JE, Preminger GM, Berger Y, Denstedt JD, Goldstone L, Segura JW, et al. Use of a temporary ureteral drainage stent after uncomplicated ureteroscopy: results from a phase II clinical trial. J Urol. 2003;169(5):1682–8.PubMedCrossRefGoogle Scholar
  38. 38.
    Chew BH, Lange D, Paterson RF, Hendlin K, Monga M, Clinkscales KW, et al. Next generation biodegradable ureteral stent in a yucatan pig model. J Urol. 2010;183(2):765–71.PubMedCrossRefGoogle Scholar
  39. 39.
    Chew BH, Paterson RF, Clinkscales KW, Levine BS, Shalaby SW, Lange D. The in vivo evaluation of the third generation biodegradable uriprene™ stent—a novel approach to avoiding the forgotten stent syndrome. J Urol. 2013;189(2):719–25.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Section of Laparoscopy and Endourology, Texas A&M College of Medicine, Scott & White Memorial HospitalTempleUSA

Personalised recommendations